Colorectal cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 6
• KRAS 57
• PD-1 108
• BRAF 35
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 30
• HER2 37
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• AMPK 0
• JNK 0
• PTEN 1
• YAP 0
• MYC 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• NLRP3 0
• TNF 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• MEK 1
• CDK4/6 2
• CD47 1
• BRCA1 1
• FGFR 0
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 14,795 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Cryptosporidium Infection and Human Colorectal Cancer

  NCT04332705· Lille Catholic University· Updated 6 Nov 2026

  “No other patients could be included within the time frame.”Registry text, quoted unchanged. Source

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

  NCT05629442· Massachusetts General Hospital· Updated 4 Nov 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Terminated

  KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

  NCT05985109· Peking University Cancer Hospital & Institute· Updated 3 Nov 2026

  “The study was stopped early due to lack of efficacy.”Registry text, quoted unchanged. Source

• Suspended

  Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

  NCT07011550· M.D. Anderson Cancer Center· Updated 2 Nov 2026

  “PI Request”Registry text, quoted unchanged. Source

• Suspended

  A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

  NCT04111172· Thomas Jefferson University· Updated 28 Oct 2026

  “Protocol is with FDA review, waiting for funding to be released”Registry text, quoted unchanged. Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Updated 26 Oct 2026

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Astellas Pharma Inc· Updated 23 Oct 2026

  “Company's strategic decision”Registry text, quoted unchanged. Source

• Terminated

  The Impact of Laparotomy and Analgesia Methods on Diaphragm

  NCT06403540· Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization· Updated 22 Oct 2026

  “The study was terminated prematurely because the planned sample size could not be achieved due to insufficient participant recruitment.”Registry text, quoted unchanged. Source

• Suspended

  EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden

  NCT04840186· Oslo University Hospital· Updated 22 Oct 2026

  “Not enough patients”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• Tislelizumab in People With Colorectal Cancer

  NCT06529523· Memorial Sloan Kettering Cancer Center· Source

• The Vanguard Study: Testing a New Way to Screen for Cancer

  NCT06995898· National Cancer Institute (NCI)· Source

• Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

  NCT07715903· National Cancer Institute (NCI)· Source

• Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment

  NCT07404228· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

  NCT07662031· Washington University School of Medicine· Source

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Source

• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· EMD Serono Research & Development Institute, Inc.· Source

• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

  NCT04847063· National Cancer Institute (NCI)· Source

• Collection of Blood From Patients With Cancer

  NCT00034216· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 131
• Organoids 108
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 334
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 21
• Exome Sequencing 26
• Proteomics 102
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 207
• Liquid Biopsy 36
• Circulating Tumor DNA 119
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 195
• Machine Learning 209
• Deep Learning 141
• Cohort Studies 314
• Genome-Wide Association Study 65

• Predicting Oxaliplatin-Induced Severe Neuropathy in Colorectal Cancer Patients with Diabetic Polyneuropathy.

  J Vis Exp, Oct 2026

• Identification of Immuno-Diagnostic and Therapeutic Markers in Tumors and Inflammatory Diseases Based on Single-Cell and Machine Learning Methods.

  Hum Mutat, Oct 2026

• Infrared spectroscopy with statistical analysis and machine learning for cancer risk assessment in inflammatory bowel disease patients.

  Analyst, Oct 2026

• Transcription factor CTCF activates KIAA1199 expression to inhibit ferroptosis and promote malignant behaviors in colorectal cancer based on bioinformatics and machine learning.

  Gene, Oct 2026

• Multifunctional nanoflower-assisted catalytic hairpin assembly enables extracellular vesicles derived-microRNAs profiling for colorectal cancer diagnosis.

  Talanta, Oct 2026

• Causal decomposition framework for quantifying intervenable cancer health disparities.

  Biometrics, Oct 2026

• Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer Using Routinely Collected Clinical Data: Multicenter Retrospective Machine Learning Model Development and External Validation Study.

  JMIR Cancer, Oct 2026

• Gut microbiota signatures and machine learning-based candidate feature prioritization in advanced colorectal cancer.

  Arch Microbiol, Oct 2026

• Development of an Interpretable Triage Tool for Colorectal Polyp Risk Stratification Within a Population-Based Screening Program: Machine Learning Approach.

  JMIR Med Inform, Sept 2026

• Machine learning-supported identification of necrosis in colorectal and pancreatic cancer spheroids.

  PLoS One, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.